{
  "nctrialId": "HC-2102",
  "title": "A Randomized Double-Blind, Placebo-Controlled Multi-Center Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Sickle Cell Disease",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled Multi-Center Study of PSO-602 (phosphodiesterase-4 inhibitor) in Patients With Sickle Cell Disease",
  "sponsor": "Princess Margaret Cancer Centre",
  "indication": "Sickle Cell Disease",
  "phase": "Phase 3",
  "fileName": "HC-2102.json",
  "fileSize": 400934,
  "date": "2024-11-30",
  "completionDate": "2026-08-04",
  "drugName": "PSO-602 (phosphodiesterase-4 inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Active, not recruiting",
  "description": "This is a randomized double-blind, placebo-controlled multi-center study designed to evaluate the efficacy and safety of PSO-602 (phosphodiesterase-4 inhibitor) in patients with Sickle Cell Disease. The study will enroll approximately 428 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 21-57 years\n- Confirmed diagnosis of Sickle Cell Disease\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}